BACKGROUND: Acute lung injury (ALI) and its extreme manifestation the acute respiratory distress syndrome (ARDS) complicate a wide variety of serious medical and surgical conditions. Thioredoxin is a small ubiquitous thiol protein with redox/inflammation modulatory properties relevant to the pathogenesis of ALI. We therefore investigated whether thioredoxin is raised extracellulary in patients with ALI and whether the extent of any increase is dependent upon the nature of the precipitating insult. METHODS: Bronchoalveolar lavage (BAL) fluid and plasma samples were collected from patients with ALI (n=30) and healthy controls (n=18, plasma; n=14, BAL fluid). Lung tissue was harvested from a separate group of patients and controls (n=10). Thioredoxin was measured by ELISA in fluids and by immunohistochemistry in tissue. Interleukin (IL)-8 levels were determined by ELISA. Disease severity was assessed as APACHE II and SOFA scores. RESULTS: BAL fluid levels of thioredoxin were higher in patients with ALI than in controls (median 61.6 ng/ml (IQR 34.9-132.9) v 16.0 ng/ml (IQR 8.9-25.1), p<0.0001); plasma levels were also significantly higher. When compared with controls, sections of wax embedded lung tissue from patients with ALI showed greater positive staining for thioredoxin in alveolar macrophages and type II epithelial cells. BAL fluid levels of thioredoxin correlated with IL-8 levels in BAL fluid but not with severity of illness scores or mortality. BAL fluid levels of thioredoxin, IL-8, and neutrophils were significantly greater in patients with ALI of pulmonary origin. CONCLUSIONS: Extracellular thioredoxin levels are raised in patients with ALI, particularly of pulmonary origin, and have a significant positive association with IL-8. Extracellular thioredoxin levels could provide a useful indication of inflammation in ALI.
BACKGROUND:Acute lung injury (ALI) and its extreme manifestation the acute respiratory distress syndrome (ARDS) complicate a wide variety of serious medical and surgical conditions. Thioredoxin is a small ubiquitous thiol protein with redox/inflammation modulatory properties relevant to the pathogenesis of ALI. We therefore investigated whether thioredoxin is raised extracellulary in patients with ALI and whether the extent of any increase is dependent upon the nature of the precipitating insult. METHODS: Bronchoalveolar lavage (BAL) fluid and plasma samples were collected from patients with ALI (n=30) and healthy controls (n=18, plasma; n=14, BAL fluid). Lung tissue was harvested from a separate group of patients and controls (n=10). Thioredoxin was measured by ELISA in fluids and by immunohistochemistry in tissue. Interleukin (IL)-8 levels were determined by ELISA. Disease severity was assessed as APACHE II and SOFA scores. RESULTS: BAL fluid levels of thioredoxin were higher in patients with ALI than in controls (median 61.6 ng/ml (IQR 34.9-132.9) v 16.0 ng/ml (IQR 8.9-25.1), p<0.0001); plasma levels were also significantly higher. When compared with controls, sections of wax embedded lung tissue from patients with ALI showed greater positive staining for thioredoxin in alveolar macrophages and type II epithelial cells. BAL fluid levels of thioredoxin correlated with IL-8 levels in BAL fluid but not with severity of illness scores or mortality. BAL fluid levels of thioredoxin, IL-8, and neutrophils were significantly greater in patients with ALI of pulmonary origin. CONCLUSIONS: Extracellular thioredoxin levels are raised in patients with ALI, particularly of pulmonary origin, and have a significant positive association with IL-8. Extracellular thioredoxin levels could provide a useful indication of inflammation in ALI.
Authors: P Pelosi; D D'Onofrio; D Chiumello; S Paolo; G Chiara; V L Capelozzi; C S V Barbas; M Chiaranda; L Gattinoni Journal: Eur Respir J Suppl Date: 2003-08
Authors: Y Sumida; T Nakashima; T Yoh; Y Nakajima; H Ishikawa; H Mitsuyoshi; Y Sakamoto; T Okanoue; K Kashima; H Nakamura; J Yodoi Journal: J Hepatol Date: 2000-10 Impact factor: 25.083
Authors: Matthew E Callister; Anne Burke-Gaffney; Gregory J Quinlan; Helen Betts; Simon Nadel; Timothy W Evans Journal: Intensive Care Med Date: 2006-11-18 Impact factor: 17.440
Authors: Yvonne M W Janssen-Heininger; Brooke T Mossman; Nicholas H Heintz; Henry J Forman; Balaraman Kalyanaraman; Toren Finkel; Jonathan S Stamler; Sue Goo Rhee; Albert van der Vliet Journal: Free Radic Biol Med Date: 2008-03-27 Impact factor: 7.376
Authors: Ramesh K Ramanathan; Joe J Stephenson; Glen J Weiss; Linda A Pestano; Ann Lowe; Alton Hiscox; Rafael A Leos; Julie C Martin; Lynn Kirkpatrick; Donald A Richards Journal: Invest New Drugs Date: 2011-08-24 Impact factor: 3.850
Authors: Susannah K Leaver; Niall S MacCallum; Vasisht Pingle; Matthew B Hacking; Gregory J Quinlan; Timothy W Evans; Anne Burke-Gaffney Journal: Intensive Care Med Date: 2009-09-15 Impact factor: 17.440
Authors: Thorsten Brenner; Claudia Rosenhagen; Jochen Steppan; Christoph Lichtenstern; Jürgen Weitz; Thomas Bruckner; Eike O Martin; Ursula Hoffmann; Markus A Weigand; Stefan Hofer Journal: Mediators Inflamm Date: 2010-08-05 Impact factor: 4.711
Authors: Harvey E Marshall; Erin N Potts; Zachary T Kelleher; Jonathan S Stamler; W Michael Foster; Richard L Auten Journal: Am J Respir Crit Care Med Date: 2009-03-26 Impact factor: 21.405